Australia’s CSL Invited To Meet With U.S. FDA Over Production Standards
This article was originally published in PharmAsia News
Executive Summary
CSL of Australia has received a request from U.S. FDA to meet with senior officials of its Biotherapies unit to discuss conditions at its vaccine-production plant in the Australian state of Victoria